Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Histocompatibility Leukocyte Antigen (HLA)-A*2402 and A*0201 Restricted Peptide Vaccine Therapy in Patients With Neovascular Maculopathy

NCT00791570 is registered in ClinicalTrials.gov with Osaka University as lead sponsor.

NCT NCT00791570
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00791570 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Histocompatibility Leukocyte Antigen (HLA)-A*2402 and A*0201 Restricted Peptide Vaccine Therapy in Patients With Neovascular Maculopathy
Lead sponsor
Osaka University
Phase
Phase 1
Overall status
Completed
Start date
October 31, 2008
Completion date
April 30, 2012
Enrollment
17 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

age related macular degeneration, neovascular maculopathy